Clinical Validation of a Protein Biomarker Panel for Non-Small Cell Lung Cancer
Journal of Korean Medical Science
;
: e342-2018.
Article
in English
| WPRIM
| ID: wpr-718391
ABSTRACT
We validated the diagnostic performance of a previously developed blood-based 7-protein biomarker panel, AptoDetect™-Lung (Aptamer Sciences Inc., Pohang, Korea) using modified aptamer-based proteomic technology for lung cancer detection. Non-small cell lung cancer (NSCLC), 200 patients and benign nodule controls, 200 participants were enrolled. In a high-risk population corresponding to ≥ 55 years of age and ≥ 30 pack-years, the diagnostic performance was improved, showing 73.3% sensitivity and 90.5% specificity with an area under the curve of 0.88. AptoDetect™-Lung (Aptamer Sciences Inc.) offers the best validated performance to discriminate NSCLC from benign nodule controls in a high-risk population and could play a complementary role in lung cancer screening.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Mass Screening
/
Sensitivity and Specificity
/
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Type of study:
Diagnostic study
/
Prognostic study
/
Screening study
Limits:
Humans
Language:
English
Journal:
Journal of Korean Medical Science
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS